Sign in
SKYE Stock Price, Chart, Stats & News
Skye Bioscience, Inc.
Save
Skye Bioscience, Inc. (SKYE) does not currently pay a dividend.
17.62M
Market cap
–
Current P/E
–
Forward P/E
SKYE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.01% |
ROA | -197.52% |
ROE | -143.59% |
D/E | 0.01x |
Interest coverage ratio | -40057.55x |
SKYE valuation
P/E | – |
P/S | – |
P/B | 1.14x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | 0.04x |
EV multiple | – |
About
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
Similar securities
Based on sector and market capitalization
Report issue